237 related articles for article (PubMed ID: 25187428)
1. Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats.
Lee PC; Yang YY; Lee WP; Lee KC; Hsieh YC; Lee TY; Lin HC
J Gastroenterol Hepatol; 2015 Mar; 30(3):628-37. PubMed ID: 25187428
[TBL] [Abstract][Full Text] [Related]
2. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
3. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
[TBL] [Abstract][Full Text] [Related]
4. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
D'Amico M; Mejías M; García-Pras E; Abraldes JG; García-Pagán JC; Fernández M; Bosch J
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(10):G1191-8. PubMed ID: 22403792
[TBL] [Abstract][Full Text] [Related]
5. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
7. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
[TBL] [Abstract][Full Text] [Related]
9. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis.
Trebicka J; Hennenberg M; Schulze Pröbsting A; Laleman W; Klein S; Granzow M; Nevens F; Zaagsma J; Heller J; Sauerbruch T
Hepatology; 2009 Dec; 50(6):1924-35. PubMed ID: 19842096
[TBL] [Abstract][Full Text] [Related]
10. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.
Zhang ZQ; Qiu JF; Luo M; Sun YW; Zhao G; Chen W; Liu H; Wu ZY
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e487-93. PubMed ID: 18070013
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
12. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
[TBL] [Abstract][Full Text] [Related]
13. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
15. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
Wang D; Wang Q; Yin J; Dong R; Wang Q; Du X; Lu J
J Gastroenterol Hepatol; 2016 May; 31(5):1037-44. PubMed ID: 26487394
[TBL] [Abstract][Full Text] [Related]
16. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
18. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
19. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats.
Hsu SJ; Lee FY; Wang SS; Hsin IF; Lin TY; Huang HC; Chang CC; Chuang CL; Ho HL; Lin HC; Lee SD
Hepatology; 2015 May; 61(5):1672-84. PubMed ID: 25557829
[TBL] [Abstract][Full Text] [Related]
20. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]